US Edition
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLANTATION, FLORIDA, AUG 2 – Performant stockholders will receive $7.75 per share, a 139% premium, as Machinify aims to expand healthcare payments intelligence and reduce administrative costs, the companies said.
- Performant Healthcare, Inc. announced its Inducement Awards were granted to Dr. Yarema for employment with ImageneBio, in accordance with Nasdaq rules.
- Performant Healthcare, Inc.'s board of directors and executive leadership team unanimously approved, concluding this path is the best outcome.
- Performant Healthcare, Inc. stockholders are set to receive $7.75 in cash per share, representing a premium of approximately 195% to the 90-day VWAP of $2.63.
- Subject to approvals, the transaction is set to complete by the end of 2025, and the combined company will deliver quality, timely payments at reduced costs.
- With the combined platform, Machinify will support healthcare clients including the Centers for Medicare and Medicaid and state and local governments, David Pierre said it will accelerate Performant’s mission.
39 Articles
39 Articles
The Berkshire Eagle
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 28, 2025, TransMedics…
Inside Halton
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new…
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 'Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units ('RSUs”) to four newly hired employees.
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
